A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Stanford University
Thomas Jefferson University
Incyte Corporation
Eilean Therapeutics
Eilean Therapeutics
National Cancer Institute (NCI)
University of Alabama at Birmingham
National Cancer Institute (NCI)
Karyopharm Therapeutics Inc
University of Turin, Italy
Ohio State University Comprehensive Cancer Center
Incyte Corporation
Incyte Corporation
University of Rochester
Merck Sharp & Dohme LLC
Incyte Corporation
M.D. Anderson Cancer Center
Prelude Therapeutics
iOnctura
University of Southern California
City of Hope Medical Center
Incyte Corporation
AbbVie
University Hospital, Brest
Icahn School of Medicine at Mount Sinai